This Scottish Biotech Just Raised $46M to Tackle a Silent Kidney Disease

Jan de Vries · 2026-08-07

### A Big Win for Rare Disease Research When a biotech company lands a massive funding round, it's usually worth paying attention. But when that money is aimed at a disease that affects millions yet gets far less attention than it deserves, the stakes feel even higher. That's exactly what's happening with Mironid, a Glasgow-based biopharmaceutical company that just closed a $46 million Series B financing round. The funding will push its lead drug candidate for Autosomal Dominant Polycystic Kidney Disease (ADPKD) through clinical development. If you've never heard of ADPKD, you're not alone. But here's the thing: it's the most common hereditary kidney disorder in the world, and it's a lot more serious than most people realize. ### What Is ADPKD and Why Does It Matter? ADPKD is caused by mutations in the PKD1 or PKD2 genes. These mutations lead to the uncontrolled growth of fluid-filled cysts in the kidneys. Over time, those cysts can crowd out healthy tissue, and in many cases, the kidneys eventually fail entirely. Neil Wilkie, CEO of Mironid, put it plainly: "ADPKD is the most common hereditary kidney disorder, affecting over 12 million people worldwide, with 50% of patients developing kidney failure by the age of 60." That's a staggering statistic. Half of all patients will need dialysis or a kidney transplant before they turn 60. Current treatments exist, but they come with significant side effects and don't work for everyone. That's where Mironid's approach could change the game. ### The Science Behind the Hope Mironid's lead candidate is a first-in-class small molecule that targets cyclic AMP (cAMP), a cellular signal that's active at every stage of the disease. According to the company, cAMP drives both cell proliferation and fluid secretion within the cysts. By directly targeting this signal, Mironid's approach could prevent new cysts from forming and stop existing ones from growing. Preclinical data has shown significant efficacy and a favorable safety profile, including reductions in cyst number and kidney volume. The company believes this could offer a more durable treatment option with a better side-effect profile compared to existing therapies. That's a bold claim, but the early data seems to back it up. ### Who's Backing This? The round was led by the Scottish National Investment Bank, with participation from a who's who of biotech investors, including Roche Venture Fund, Epidarex Capital, Sofinnova Partners, BioGeneration Ventures, and the University of Strathclyde. That's a high-caliber syndicate, and it speaks volumes about the potential they see in Mironid's pipeline. Paul Callaghan, Investment Director at the Scottish National Investment Bank, said: "Mironid exemplifies Scotland's growing reputation for biotech innovation, developing a new treatment approach that could improve options for people living with kidney disease." ### Beyond ADPKD: A Broader Pipeline Mironid isn't just focused on ADPKD. The company's pipeline also targets phosphodiesterase 4 (PDE4) enzymes, which play a key role in cell signaling pathways linked to disease progression. That means the same platform could potentially be applied to major inflammatory diseases and even cancer down the line. Spun out of the University of Strathclyde and Heriot-Watt University in 2015, Mironid builds on more than three decades of research into PDE biology by Professor Miles Houslay. The company is headquartered in Glasgow and operates on a research-and-development-led model, funded through venture capital and strategic investment. ### What This Funding Means The fresh capital follows an earlier Series A extension round, bringing Mironid's total funding since inception to roughly $47 million. That's a solid war chest for a company at this stage. The goal is to advance the lead candidate through clinical trials and, eventually, toward commercialization. For patients living with ADPKD, the timeline can't move fast enough. But with this kind of backing and a promising scientific approach, there's real reason for optimism. It's not every day you see a small biotech taking on a disease this big with a genuinely novel strategy. This one's worth watching. ### The Bottom Line Mironid's $46 million Series B is more than just a funding announcement. It's a signal that investors believe in the science, the team, and the potential to transform how we treat rare kidney diseases. For the 12 million people worldwide living with ADPKD, that's a ray of hope. And for the rest of us, it's a reminder that some of the most important breakthroughs in medicine happen quietly, far from the headlines.